Search 

Armoured hold the Tianyi Group layout of science and technology investment capital investment platform. Armoured capital in order to create long-term value for the purpose, committed to accelerate the transformation of scientific and technological industry and fall to the ground, accelerate the development of innovative enterprise, and industry potential industry and change. So far, has invested Zephyrm Biotechnologies, Milky Way motivation, CSTshen, companies such as the future and will continue to pay attention to the capitalization of the business process and industry, seek the change from a single financial investment to the strategy of diversifying investment.

Healthcare Consulting and Investment

Henlius (2696.HK) is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California, and commercial office in Frankfurt. The three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process.
Starting from biosimilar, Henlius presses forward with novel mAb products and immuno-oncology combination therapies with proprietary anti-PD-1 and PD-L1 mAbs as backbone. Henlius establishes a diversified product pipeline of biosimilars, bio-innovative drugs and combination therapies, and builds an integrated platform covering the whole product lifecycle including R&D, commercial-scale production and commercialization.

Keywords : Cancer, Oncology, Biologics, Biosimilar, BioInnovative, Biobetter, Monoclonal Antibody, Mabs, Tumors, Immuno oncology, PD1, PD-L1, EGFR, VEGF, HER2,

digital healthcare company

Top medical device company in China focused on cardiovascular, surgical robotics and ten more fields.

Well renown venture capital firm in China.

Relying on advantage of the platform resource and industrial agglomeration of dongsheng science and technology park in zhongguancun, ruisheng investment buite the whole chain investment system. Fund manager: shenzhen ruisheng equity investment fund partnership (limited partnership) (registration code: P1034628). To early stage venture fund, incubation fund, late for partial equity investment for the project has a mezzanine fund, stock bonds combined investment, m&a, etc., at the same time, in which foreign involved as an LP covers health, artificial intelligence, new materials, consumption and new energy fields of four professional fund, key node layout industrial chain.

成立于1999年，国内首批创投机构

simcere pharmaceutical group

MEDICAL AND MEDICINE INTL COOPAERATION AND INVESTMENT